Enable Injections announced that Sanofi is making a $30 million investment in the Cincinnati-based drug delivery company to accelerate a manufacturing build-out, bolster supply chain capabilities, and support commercial growth for its enFuse on-body delivery system.
Enable develops and manufactures the enFuse On-Body Delivery System, a hands-free wearable injector designed to administer large-volume medicines subcutaneously with a push-button start and a hidden, retractable needle. The company said the additional capital is intended to help it meet rising demand from pharmaceutical partners as programs progress toward commercialization.
The investment builds on a multi-year relationship between Enable and Sanofi. Enable said its on-body injector was used in Sanofi-sponsored Sarclisa clinical studies, including the IRAKLIA phase 3 trial in newly diagnosed multiple myeloma and the IZALCO phase 2 study in relapsed or refractory multiple myeloma, both presented at the American Society of Clinical Oncology annual meeting in June 2025. Enable said use of the on-body injector for Sarclisa is currently under regulatory review.
Enable has raised significant capital previously and has positioned manufacturing expansion as a key priority. The company said Sanofi led a $50 million Series B round in 2018, followed by a formal partnership announcement in 2019. Enable later closed a $215 million Series C financing in January 2022 led by Magnetar Capital, with participation from Sanofi and other institutional investors, and continued backing from existing regional and strategic investors.
In 2024, Enable announced plans for a 90,000-square-foot Manufacturing Center of Excellence in Springdale, Ohio, along with enhancements to its corporate headquarters in Evendale, Ohio, as part of a broader push toward in-house, large-scale production and commercialization. Enable also said the enFuse technology received its first U.S. FDA approval as part of a combination product in 2023 and has since secured device marketing authorizations in multiple markets outside the U.S.
KEY QUOTE:
“This investment from one of our key partners shows support of the enFuse platform and our shared commitment to making large-volume subcutaneous injectable therapies more convenient for patients, including oncology. Expanding our manufacturing capabilities is key to meeting the needs of our partners while bringing innovative treatment options to patients, worldwide.”
Michael D. Hooven, Chairman And CEO, Enable Injections
